Placebo

NEW YORK (Reuters Health) - Knee pain appears to decrease up to one year after "prolotherapy," a series of sugar water injections at the site of the pain, according to a new study. Previous research on the therapy that suggested positive effects was...

COPENHAGEN (Reuters) - Denmark's Novo Nordisk, the world's biggest insulin producer, said Phase III study results had shown people treated with its liraglutide drug had an 8 percent weight loss. "These data, together with previously reported Phase III...

(Reuters) - A new type of asthma drug meant to attack the underlying causes of the respiratory disease slashed episodes by 87 percent in a mid-stage trial, making it a potential game changer for patients with moderate to severe disease, researchers said...

(Reuters) - AcelRX Pharmaceuticals Inc said its experimental treatment for post-operative pain met its main goal in a late-stage trial of patients who had undergone knee or hip replacement surgery, sending its shares up 15 percent. AcelRX said its...

WASHINGTON (Reuters) - Merck & Co's experimental insomnia drug suvorexant appears generally effective, according to reviewers at the U.S. Food and Drug Administration, but they questioned the company's proposed dosing levels. The reviewers posted their...

(Reuters) - XenoPort Inc said it would stop development of an experimental multiple sclerosis treatment it planned to launch in 2015 after a late-stage trial failed to show significant improvement over a placebo. Shares of the company fell 26 percent...

Veterinarian Kevin Fitzgerald has an article in the May/June issue of AKC Family Dog magazine titled “Kennel Concerns and Laser Therapy.” I selected the laser therapy segment because it concerns pain therapy and everyone is interested in...

Dear Pharmacist: I've had migraine headaches for 11 years and live on triptan drugs and ibuprofen. There must be something else I can do. Please lend some sensible Suzy insight. — J.C., Tucson, Ariz. Dear J.C.: The sensible thing for me to do is...

May 7 (Reuters) - Baxter International Inc said a late-stage study of its experimental drug to treat Alzheimer's disease failed to reduce the decline of cognitive functions and preserve functional abilities. The trial showed that after 18 months of...

Baxter International Inc. said Tuesday that a late-stage clinical trial of a plasma product it was testing to treat patients with Alzheimer's disease failed to slow cognitive decline and preserve physical function, sending its shares down more than 3...

When the president and CEO of Boehringer Ingelheim USA starts to talk about the company's most dramatic failure in the last five years, a certain sheepish tone creeps into his voice. He thinks he's going to have to explain the disease the drug was...

AbbVie said Tuesday that it is teaming up with a California drug company to develop an oral treatment for celiac disease. Celiac disease is the most common autoimmune disease, affecting about 6 million people in the U.S. and Europe.  Those affected can'...